This week’s DeviceTalks Weekly podcast shares the stories of the professionals who are working to get the new COVID-19 vaccines into the hands – and arms – of the front-line fighters and people at greatest risk. Leading off, Elizabeth Woody, SVP of public affairs at BD, explains how the company is preparing for the increasing […]
Tandem Diabetes Care
Canada approves Tandem Diabetes Caree’s advanced hybrid closed-loop insulin pump
Tandem Diabetes Care (NSDQ:TNDM) announced today that Health Canada has approved its t:slim X2 insulin pump with Control-IQ technology. The news comes nearly a year after the U.S. launch of the t:slim X2 with Control-IQ. Get the full story on our sister site Drug Delivery Business News.
Tandem Diabetes slides after hours on mixed bag Q3
Tandem Diabetes Care (NSDQ:TNDM) shares took a hit after hours today on third-quarter results that were mixed compared to the consensus forecast. The San Diego-based insulin delivery and diabetes technology company posted losses of -$9.4 million, or -15¢ per share, on sales of $123.6 million for the three months ended Sept. 30, 2020, for a bottom-line […]
MedTech 100 roundup: Industry hits another mid-pandemic high
Despite a minor regression week-over-week, the medtech industry’s stocks hit another milestone as the COVID-19 rebound remains in progress. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — sat at 89.01 points at the end of last week (July 31). Overall, medtech stocks saw a -0.3% increase from the […]
Tandem Diabetes posts $27m Q2 loss, reinstates earlier guidance
Tandem Diabetes Care (NSDQ:TNDM) posted Street-beating second-quarter sales and missed badly on earnings, but reinstated its earlier full-year 2020 guidance. The San Diego-based company — maker of insulin pumps and other diabetes management devices — reported a loss of -$27.1 million or -0.45¢ per share, on sales of $109.2 million for the three months ended June […]
Medtronic, Tandem Diabetes Care bury the hatchet on potential IP disputes
Two major insulin pump makers — Medtronic (NYSE:MDT) and Tandem Diabetes Care (NSDQ:TNDM) — announced today that they’ve inked a non-exclusive patent cross-license agreement related to diabetes treatment tech. The companies said the agreement will allow them to focus on innovation while avoiding the distraction of potential legal disagreements. The deal could be but another example of […]
